UNUM THERAPEUTICS has a total of 15 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2015. It filed its patents most often in WIPO (World Intellectual Property Organization), EPO (European Patent Office) and Singapore. Its main competitors in its focus markets biotechnology and pharmaceuticals are SANGAMO THERAPEUTICS FRANCE, ZHEJIANG DOER BIOLOGICS CORP and ADICET BIO INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 4 | |
#2 | EPO (European Patent Office) | 2 | |
#3 | Singapore | 2 | |
#4 | Australia | 1 | |
#5 | Brazil | 1 | |
#6 | Canada | 1 | |
#7 | China | 1 | |
#8 | Israel | 1 | |
#9 | Republic of Korea | 1 | |
#10 | Mexico | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Medical preparations | |
#3 | Microorganisms | |
#4 | Therapeutic chemical compounds |
# | Name | Total Patents |
---|---|---|
#1 | Wilson Charles | 11 |
#2 | Mcginness Kathleen | 10 |
#3 | Ettenberg Seth | 4 |
#4 | Huet Heather | 3 |
#5 | Kathleen Mcginness | 2 |
#6 | Charles Wilson | 1 |
#7 | Choi Eugene | 1 |
#8 | Cheema Tooba | 1 |
#9 | Fray Michael | 1 |
Publication | Filing date | Title |
---|---|---|
WO2017205254A1 | Immune cells expressing antibody-coupled t-cell receptor (actr) for use in inhibiting cancer cells expressing surface immunoglobulin | |
WO2017177217A2 | Chimeric receptors and uses thereof in immune therapy | |
WO2017161333A1 | Modified chimeric receptors and uses thereof in immune therapy | |
CN107074969A | Chimerical receptor and its application in immunization therapy |